Literature DB >> 12559112

Mu-opioid receptors are located postsynaptically and endomorphin-1 inhibits voltage-gated calcium currents in premotor cardiac parasympathetic neurons in the rat nucleus ambiguus.

M Irnaten1, S A Aicher, J Wang, P Venkatesan, C Evans, S Baxi, D Mendelowitz.   

Abstract

Activation of opioid receptors in the CNS evokes a dramatic decrease in heart rate which is mediated by increases in inhibitory parasympathetic activity to the heart. Injection of opiates into the nucleus ambiguus, where premotor cardiac parasympathetic nucleus ambiguus neurons are located elicits an increase in parasympathetic cardiac activity and bradycardia. However, the mechanisms responsible for altering the activity of premotor cardiac parasympathetic nucleus ambiguus neurons is unknown. This study examined at the electron microscopic level whether premotor cardiac parasympathetic nucleus ambiguus neurons possess postsynaptic opioid receptors and whether mu-opioid receptor agonists alter voltage-gated calcium currents in these neurons. Premotor cardiac parasympathetic nucleus ambiguus neurons were identified in the rat using retrograde fluorescent tracers. One series of experiments utilized dual-labeling immunocytochemical methods combined with electron microscopic analysis to determine if premotor cardiac parasympathetic nucleus ambiguus neurons contain mu-opioid receptors. In a second series of experiments whole cell patch clamp methodologies were used to determine whether activation of postsynaptic opioid receptors altered voltage-gated calcium currents in premotor cardiac parasympathetic nucleus ambiguus neurons in brainstem slices. The perikarya and 78% of the dendrites of premotor cardiac parasympathetic nucleus ambiguus neurons contain mu-opioid receptors. Voltage-gated calcium currents in premotor cardiac parasympathetic nucleus ambiguus neurons were comprised nearly entirely of omega-agatoxin-sensitive P/Q-type voltage-gated calcium currents. Activation of mu-opioid receptors inhibited these voltage-gated calcium currents and this inhibition was blocked by pretreatment with pertusis toxin. The mu-opioid receptor agonist endomorphin-1, but not the mu-opioid receptor agonist endomorphin-2, inhibited the calcium currents. In summary, mu-opioid receptors are located postsynaptically on premotor cardiac parasympathetic nucleus ambiguus neurons. The mu-opioid receptor agonist endomorphin1 inhibited the omega-agatoxin-sensitive P/Q-type voltage-gated calcium currents in premotor cardiac vagal nucleus ambiguus neurons. This inhibition is mediated via a G-protein mediated pathway which was blocked by pretreatment with pertusis toxin. It is possible that the inhibition of calcium currents may act to indirectly facilitate the activity of premotor cardiac parasympathetic nucleus ambiguus neurons by disinhibition, such as by a reduction in inhibitory calcium activated potassium currents. Copyright 2003 IBRO

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559112     DOI: 10.1016/s0306-4522(02)00657-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  12 in total

1.  Urocortin 3 elevates cytosolic calcium in nucleus ambiguus neurons.

Authors:  G Cristina Brailoiu; Elena Deliu; Andrei A Tica; Vineet C Chitravanshi; Eugen Brailoiu
Journal:  J Neurochem       Date:  2012-08-03       Impact factor: 5.372

2.  Effects of VPAC1 activation in nucleus ambiguus neurons.

Authors:  Florin Liviu Gherghina; Andrei Adrian Tica; Elena Deliu; Mary E Abood; G Cristina Brailoiu; Eugen Brailoiu
Journal:  Brain Res       Date:  2016-12-30       Impact factor: 3.252

Review 3.  The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Jing Yu; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015-07-15       Impact factor: 2.581

4.  Evidence for role of acid-sensing ion channels in nucleus ambiguus neurons: essential differences in anesthetized versus awake rats.

Authors:  G Cristina Brailoiu; Elena Deliu; Joseph B Altmann; Vineet Chitravanshi; Eugen Brailoiu
Journal:  J Comp Physiol B       Date:  2014-04-22       Impact factor: 2.200

5.  Nesfatin-1 activates cardiac vagal neurons of nucleus ambiguus and elicits bradycardia in conscious rats.

Authors:  G Cristina Brailoiu; Elena Deliu; Andrei A Tica; Joseph E Rabinowitz; Douglas G Tilley; Khalid Benamar; Walter J Koch; Eugen Brailoiu
Journal:  J Neurochem       Date:  2013-07-19       Impact factor: 5.372

6.  Non-motor multiple system atrophy associated with sudden death: pathological observations of autonomic nuclei.

Authors:  Yuichi Riku; Hirohisa Watanabe; Maya Mimuro; Yasushi Iwasaki; Mizuki Ito; Masahisa Katsuno; Gen Sobue; Mari Yoshida
Journal:  J Neurol       Date:  2017-09-22       Impact factor: 4.849

7.  Urotensin II promotes vagal-mediated bradycardia by activating cardiac-projecting parasympathetic neurons of nucleus ambiguus.

Authors:  Gabriela Cristina Brailoiu; Elena Deliu; Joseph E Rabinowitz; Douglas G Tilley; Walter J Koch; Eugen Brailoiu
Journal:  J Neurochem       Date:  2014-03-06       Impact factor: 5.372

8.  Aldosterone increases cardiac vagal tone via G protein-coupled oestrogen receptor activation.

Authors:  G Cristina Brailoiu; Khalid Benamar; Jeffrey B Arterburn; Erhe Gao; Joseph E Rabinowitz; Walter J Koch; Eugen Brailoiu
Journal:  J Physiol       Date:  2013-07-22       Impact factor: 5.182

9.  HIV-1-Tat excites cardiac parasympathetic neurons of nucleus ambiguus and triggers prolonged bradycardia in conscious rats.

Authors:  Eugen Brailoiu; Elena Deliu; Romeo A Sporici; Khalid Benamar; G Cristina Brailoiu
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-04-02       Impact factor: 3.619

10.  Parasympathetic preganglionic cardiac motoneurons labeled after voluntary diving.

Authors:  W Michael Panneton; A Michael Anch; Whitney M Panneton; Qi Gan
Journal:  Front Physiol       Date:  2014-01-28       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.